All In Biotech

Drug Trial Radar · NCT01257737

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

Long Term Use of HPN-100 in Urea Cycle Disorders

Last checked: Nov 20, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

88

Actual

Start

Oct 4, 2010

Primary completion

Feb 16, 2017

Study completion Feb 16, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Dec 10, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, long-term safety study of HPN-100 (RAVICTI; glycerol phenylbutyrate) in participants with a urea cycle disorder (UCD) who completed the safety extensions of HPN-100-005 (NCT00947544; HPN-100-005SE), HPN-100-006 (NCT00947297; HPN-100-007), or HPN-100-012 (NCT01347073; HPN-100-012SE). The initial studies were 1- to 2-week crossover studies, and their associated safety extensions were 12-month, open-label studies. All participants who completed the initial studies were eligible to enroll in the associated safety extension studies, and new participants were also permitted to enroll directly into the safety extension studies.

Conditions

  • Urea Cycle Disorders

Interventions

  • HPN-100Drug

    Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least One Adverse EventTime frame: From the time of informed consent until 7 days after the last dose of study drug, up to 66 months

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • UCLA Pediatrics/Genetics

    Los Angeles, California

  • Stanford University School of Medicine

    Palo Alto, California

  • Denver Children's Hospital

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Maine Medical Center

    Portland, Maine

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • Mount Sinai School of Medicine

    New York, New York

  • University Hospitals Case Medical Center

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Children's Hospital of Pittsburg of UPMC

    Pittsburgh, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.